Oral daily and intermittent ibandronate provide significant and sustained reductions in height loss in postmenopausal osteoporosis: Results from the bone study

被引：0
|
作者：
Delmas, PD
Hoiseth, A
Gilbride, J
Schimmer, RC
Chesnut, CH
机构：
[1] Univ Lyon 1, F-69365 Lyon, France
[2] INSERM, Res Unit 403, Lyon, France
[3] Sentrum Rontgeninst, Oslo, Norway
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Univ Washington, Seattle, WA 98195 USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] Oral daily and intermittent ibandronate significantly reduce height loss in postmenopausal osteoporosis.
    Chesnut, CH
    Skag, A
    Hoiseth, A
    Gilbride, J
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S157 - S157
  • [2] Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study
    Recker R.R.
    Weinstein R.S.
    Chesnut III C.H.
    Schimmer R.C.
    Mahoney P.
    Hughes C.
    Bonvoisin B.
    Meunier P.J.
    Osteoporosis International, 2004, 15 (3) : 231 - 237
  • [3] Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
    Delmas, PD
    Recker, RR
    Chesnut, CH
    Skag, A
    Stakkestad, JA
    Emkey, R
    Gilbride, J
    Schimmer, RC
    Christiansen, C
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (10) : 792 - 798
  • [4] Daily and intermittent oral ibandronate: An evaluation of bone histomorphometry in postmenopausal osteoporosis.
    Recker, RR
    Meunier, PJ
    Chesnut, CH
    Hughes, C
    Bonvoisin, B
    Weinstein, RS
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S448 - S449
  • [5] Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
    P. D. Delmas
    R. R. Recker
    C. H. Chesnut
    A. Skag
    J. A. Stakkestad
    R. Emkey
    J. Gilbride
    R. C. Schimmer
    C. Christiansen
    Osteoporosis International, 2004, 15 : 792 - 798
  • [6] Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis
    McClung, MR
    Wasnich, RD
    Recker, R
    Cauley, JA
    Chesnut, CH
    Ensrud, KE
    Burdeska, A
    Mills, T
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (01) : 11 - 18
  • [7] Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis.
    McClung, M
    Wasnich, RD
    Recker, R
    Cauley, JA
    Ensrud, K
    Burdeska, A
    Mahoney, P
    Hughes, C
    Chesnut, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S157 - S157
  • [8] Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis
    Riis, BJ
    Ise, J
    Von Stein, T
    Bagger, Y
    Christiansen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (10) : 1871 - 1878
  • [9] Oral monthly ibandronate in postmenopausal bone loss: Results from the Monthly Oral Pilot Study (MOPS).
    Reginster, JY
    Wiese, C
    Wilson, K
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S373 - S373
  • [10] Monthly oral ibandronate is at least as effective as oral daily ibandronate in postmenopausal osteoporosis: 1-Year results from MOBILE.
    Miller, PD
    Drezner, HK
    Delmas, PD
    Stakkestad, JA
    Hughes, C
    Bonvoisin, B
    Reginster, JY
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
12345